These findings are similar to that reported by Zhou et al (2020) who found that inflammasome-related genes (NLRP3, NF-κB1, IL-1β) were highly expressed in BM cells from MPN patients and the increased expression was associated with JAK2V617F mutation, white blood cell counts and splenomegaly and suggested that these findings point out for novel biomarkers which may be a suggested target for MPN control. Here, NFKB1 is linked to myeloproliferative disorder.